Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 39
HOS-139854 · Präparat HOS-098408
Inhibitors of OATP1B1 or 3 Co-administration of letermovir with medicinal products that are inhibitors of OATP1B1/3 transporters may result in increased letermovir plasma concentrations. If letermovir is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of letermovir is 240 mg once daily in adult and paediatric patients weighing at least 30 kg (see Table 2 and sections 4.2 and 5.2). If intravenous letermovir is co-administered with cyclosporine in paediatric patients weighing less than 30 kg, dose adjustment is not required (see Table 2 and sections 4.2 and 5.2). Caution is advised if other OATP1B1/3 inhibitors are added to letermovir combined with cyclosporine. -Examples of OATP1B1 inhibitors include gemfibrozil, erythromycin, clarithromycin, and several protease inhibitors (atazanavir, simeprevir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) gemfibrozil (HOS-088403) clarithromycin (HOS-084517) erythromycin (HOS-084514) simeprevir (HOS-086302) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 248c70c07d2b4f72a26bb2904cffb47a0df6f8f50d5d13e99be906410ca6b10b · Zeichen 2091–2939 im Abschnitt